DDInter1328 DDInter1676
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Olaratumab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Olaratumab may lead to a major life threatening interaction when taken with Leflunomide